The global Oral Antianginal Drugs market  size is set to grow from  US$ 6138 million in 2025 to US$ 7741 million in 2031; it is expected to grow at a CAGR of 3.9% from 2025 to 2031.

Global Oral Antianginal Drugs Market Growth and Outlook 2025-31

The global Oral Antianginal Drugs market size is predicted to grow from US$ 6138 million in 2025 to US$ 7741 million in 2031; it is expected to grow at a CAGR of 3.9% from 2025 to 2031. Angina pectoris drugs are medications used to manage and alleviate the symptoms of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. These drugs aim to improve blood flow, reduce the hearts workload, and prevent the occurrence of angina episodes. Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris. LPI (LP Information) newest research report, the Oral Antianginal Drugs Industry Forecast looks at past sales and reviews total world Oral Antianginal Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Antianginal Drugs sales for 2025 through 2031. With Oral Antianginal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Antianginal Drugs industry. This Insight Report provides a comprehensive analysis of the global Oral Antianginal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Antianginal Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Oral Antianginal Drugs market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Antianginal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Antianginal Drugs. This report presents a comprehensive overview, market shares, and growth opportunities of Oral Antianginal Drugs market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Beta Blockers &nbsp;&nbsp;&nbsp; Calcium Antagonists &nbsp;&nbsp;&nbsp; Anticoagulants &nbsp;&nbsp;&nbsp; Anti-Platelets &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinics &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Pfizer Inc. &nbsp;&nbsp;&nbsp; Bayer AG &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc. &nbsp;&nbsp;&nbsp; Merck & Co., Inc. &nbsp;&nbsp;&nbsp; Amgen Inc. &nbsp;&nbsp;&nbsp; Eli Lilly and Company &nbsp;&nbsp;&nbsp; Otsuka Pharmaceutical Co., Ltd. &nbsp;&nbsp;&nbsp; Sanofi S.A. &nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Oral Antianginal Drugs Market Size (2020-2031) &nbsp;2.1.2 Oral Antianginal Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Oral Antianginal Drugs by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Oral Antianginal Drugs Segment by Type &nbsp;2.2.1 Beta Blockers &nbsp;2.2.2 Calcium Antagonists &nbsp;2.2.3 Anticoagulants &nbsp;2.2.4 Anti-Platelets &nbsp;2.2.5 Others &nbsp;2.3 Oral Antianginal Drugs Market Size by Type &nbsp;2.3.1 Oral Antianginal Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Oral Antianginal Drugs Market Size Market Share by Type (2020-2025) &nbsp;2.4 Oral Antianginal Drugs Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinics &nbsp;2.4.3 Others &nbsp;2.5 Oral Antianginal Drugs Market Size by Application &nbsp;2.5.1 Oral Antianginal Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Oral Antianginal Drugs Market Size Market Share by Application (2020-2025) 3 Oral Antianginal Drugs Market Size by Player &nbsp;3.1 Oral Antianginal Drugs Market Size Market Share by Player &nbsp;3.1.1 Global Oral Antianginal Drugs Revenue by Player (2020-2025) &nbsp;3.1.2 Global Oral Antianginal Drugs Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Oral Antianginal Drugs Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Oral Antianginal Drugs by Region &nbsp;4.1 Oral Antianginal Drugs Market Size by Region (2020-2025) &nbsp;4.2 Global Oral Antianginal Drugs Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Oral Antianginal Drugs Market Size Growth (2020-2025) &nbsp;4.4 APAC Oral Antianginal Drugs Market Size Growth (2020-2025) &nbsp;4.5 Europe Oral Antianginal Drugs Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Oral Antianginal Drugs Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Oral Antianginal Drugs Market Size by Country (2020-2025) &nbsp;5.2 Americas Oral Antianginal Drugs Market Size by Type (2020-2025) &nbsp;5.3 Americas Oral Antianginal Drugs Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Oral Antianginal Drugs Market Size by Region (2020-2025) &nbsp;6.2 APAC Oral Antianginal Drugs Market Size by Type (2020-2025) &nbsp;6.3 APAC Oral Antianginal Drugs Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Oral Antianginal Drugs Market Size by Country (2020-2025) &nbsp;7.2 Europe Oral Antianginal Drugs Market Size by Type (2020-2025) &nbsp;7.3 Europe Oral Antianginal Drugs Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Oral Antianginal Drugs by Region (2020-2025) &nbsp;8.2 Middle East & Africa Oral Antianginal Drugs Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Oral Antianginal Drugs Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Oral Antianginal Drugs Market Forecast &nbsp;10.1 Global Oral Antianginal Drugs Forecast by Region (2026-2031) &nbsp;10.1.1 Global Oral Antianginal Drugs Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Oral Antianginal Drugs Forecast &nbsp;10.1.3 APAC Oral Antianginal Drugs Forecast &nbsp;10.1.4 Europe Oral Antianginal Drugs Forecast &nbsp;10.1.5 Middle East & Africa Oral Antianginal Drugs Forecast &nbsp;10.2 Americas Oral Antianginal Drugs Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Oral Antianginal Drugs Forecast &nbsp;10.2.2 Canada Market Oral Antianginal Drugs Forecast &nbsp;10.2.3 Mexico Market Oral Antianginal Drugs Forecast &nbsp;10.2.4 Brazil Market Oral Antianginal Drugs Forecast &nbsp;10.3 APAC Oral Antianginal Drugs Forecast by Region (2026-2031) &nbsp;10.3.1 China Oral Antianginal Drugs Market Forecast &nbsp;10.3.2 Japan Market Oral Antianginal Drugs Forecast &nbsp;10.3.3 Korea Market Oral Antianginal Drugs Forecast &nbsp;10.3.4 Southeast Asia Market Oral Antianginal Drugs Forecast &nbsp;10.3.5 India Market Oral Antianginal Drugs Forecast &nbsp;10.3.6 Australia Market Oral Antianginal Drugs Forecast &nbsp;10.4 Europe Oral Antianginal Drugs Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Oral Antianginal Drugs Forecast &nbsp;10.4.2 France Market Oral Antianginal Drugs Forecast &nbsp;10.4.3 UK Market Oral Antianginal Drugs Forecast &nbsp;10.4.4 Italy Market Oral Antianginal Drugs Forecast &nbsp;10.4.5 Russia Market Oral Antianginal Drugs Forecast &nbsp;10.5 Middle East & Africa Oral Antianginal Drugs Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Oral Antianginal Drugs Forecast &nbsp;10.5.2 South Africa Market Oral Antianginal Drugs Forecast &nbsp;10.5.3 Israel Market Oral Antianginal Drugs Forecast &nbsp;10.5.4 Turkey Market Oral Antianginal Drugs Forecast &nbsp;10.6 Global Oral Antianginal Drugs Forecast by Type (2026-2031) &nbsp;10.7 Global Oral Antianginal Drugs Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Oral Antianginal Drugs Forecast 11 Key Players Analysis &nbsp;11.1 Pfizer Inc. &nbsp;11.1.1 Pfizer Inc. Company Information &nbsp;11.1.2 Pfizer Inc. Oral Antianginal Drugs Product Offered &nbsp;11.1.3 Pfizer Inc. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Pfizer Inc. Main Business Overview &nbsp;11.1.5 Pfizer Inc. Latest Developments &nbsp;11.2 Bayer AG &nbsp;11.2.1 Bayer AG Company Information &nbsp;11.2.2 Bayer AG Oral Antianginal Drugs Product Offered &nbsp;11.2.3 Bayer AG Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Bayer AG Main Business Overview &nbsp;11.2.5 Bayer AG Latest Developments &nbsp;11.3 AstraZeneca &nbsp;11.3.1 AstraZeneca Company Information &nbsp;11.3.2 AstraZeneca Oral Antianginal Drugs Product Offered &nbsp;11.3.3 AstraZeneca Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 AstraZeneca Main Business Overview &nbsp;11.3.5 AstraZeneca Latest Developments &nbsp;11.4 Gilead Sciences &nbsp;11.4.1 Gilead Sciences Company Information &nbsp;11.4.2 Gilead Sciences Oral Antianginal Drugs Product Offered &nbsp;11.4.3 Gilead Sciences Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Gilead Sciences Main Business Overview &nbsp;11.4.5 Gilead Sciences Latest Developments &nbsp;11.5 Novartis AG &nbsp;11.5.1 Novartis AG Company Information &nbsp;11.5.2 Novartis AG Oral Antianginal Drugs Product Offered &nbsp;11.5.3 Novartis AG Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Novartis AG Main Business Overview &nbsp;11.5.5 Novartis AG Latest Developments &nbsp;11.6 GlaxoSmithKline Plc. &nbsp;11.6.1 GlaxoSmithKline Plc. Company Information &nbsp;11.6.2 GlaxoSmithKline Plc. Oral Antianginal Drugs Product Offered &nbsp;11.6.3 GlaxoSmithKline Plc. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 GlaxoSmithKline Plc. Main Business Overview &nbsp;11.6.5 GlaxoSmithKline Plc. Latest Developments &nbsp;11.7 Merck & Co., Inc. &nbsp;11.7.1 Merck & Co., Inc. Company Information &nbsp;11.7.2 Merck & Co., Inc. Oral Antianginal Drugs Product Offered &nbsp;11.7.3 Merck & Co., Inc. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Merck & Co., Inc. Main Business Overview &nbsp;11.7.5 Merck & Co., Inc. Latest Developments &nbsp;11.8 Amgen Inc. &nbsp;11.8.1 Amgen Inc. Company Information &nbsp;11.8.2 Amgen Inc. Oral Antianginal Drugs Product Offered &nbsp;11.8.3 Amgen Inc. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Amgen Inc. Main Business Overview &nbsp;11.8.5 Amgen Inc. Latest Developments &nbsp;11.9 Eli Lilly and Company &nbsp;11.9.1 Eli Lilly and Company Company Information &nbsp;11.9.2 Eli Lilly and Company Oral Antianginal Drugs Product Offered &nbsp;11.9.3 Eli Lilly and Company Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Eli Lilly and Company Main Business Overview &nbsp;11.9.5 Eli Lilly and Company Latest Developments &nbsp;11.10 Otsuka Pharmaceutical Co., Ltd. &nbsp;11.10.1 Otsuka Pharmaceutical Co., Ltd. Company Information &nbsp;11.10.2 Otsuka Pharmaceutical Co., Ltd. Oral Antianginal Drugs Product Offered &nbsp;11.10.3 Otsuka Pharmaceutical Co., Ltd. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Otsuka Pharmaceutical Co., Ltd. Main Business Overview &nbsp;11.10.5 Otsuka Pharmaceutical Co., Ltd. Latest Developments &nbsp;11.11 Sanofi S.A. &nbsp;11.11.1 Sanofi S.A. Company Information &nbsp;11.11.2 Sanofi S.A. Oral Antianginal Drugs Product Offered &nbsp;11.11.3 Sanofi S.A. Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Sanofi S.A. Main Business Overview &nbsp;11.11.5 Sanofi S.A. Latest Developments &nbsp;11.12 Boehringer Ingelheim International GmbH &nbsp;11.12.1 Boehringer Ingelheim International GmbH Company Information &nbsp;11.12.2 Boehringer Ingelheim International GmbH Oral Antianginal Drugs Product Offered &nbsp;11.12.3 Boehringer Ingelheim International GmbH Oral Antianginal Drugs Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Boehringer Ingelheim International GmbH Main Business Overview &nbsp;11.12.5 Boehringer Ingelheim International GmbH Latest Developments 12 Research Findings and Conclusion

Report	Global Oral Antianginal Drugs Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI16159

Buyer Information

Order Summary